Sun Pharma books Rs 346 crore Organon deal costs in Q2; profit falls 36%

Sun Pharmaceutical Industries experienced a significant decline in net profit during the September quarter of FY27. The company incurred acquisition-related costs of Rs 346.16 crore while preparing for the Organon acquisition. Revenue from operations increased by 11.9% compared to the same quarter last year. An important settlement of Rs 922.67 crore was reached concerning a litigation in the US. The transaction with Organon is expected to close in Q4 FY27.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lVIyPuW
via IFTTT

Read More

Omron Healthcare eyes Chennai as global manufacturing hub, targets 3 million BP monitors by 2028

Omron Healthcare has commenced full-scale production at its new facility near Chennai for blood pressure monitors. The company aims to produce three million monitors annually by 2028 for the Indian market. Initially, all produced devices will serve local consumers to address cardiovascular health challenges. Omron is also working towards increasing domestic sourcing of components to support local manufacturing initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2JSVslj
via IFTTT

Read More

NPPA list brings little relief: No price cut for 25% cancer drugs

Nearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across 643 packs is 38.22%. Several high-cost patented medicines remain unchanged, prompting patient advocates to question how much relief the trade-margin cap will actually deliver when the new prices take effect on November 9.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hqpvYDO
via IFTTT

Read More

India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: Pharmexcil

India's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driven by strong demand from Europe, ASEAN, and Latin America. Shipments included drug formulations, biologicals, bulk drugs, and surgical products. Exports to key regions, particularly Europe and ASEAN, rose significantly during this period. Industry leaders emphasized the need for India to enhance its pharmaceutical innovation and manufacturing capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1prYPNv
via IFTTT

Read More

Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini Piramal

In a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The company is actively diversifying its supply chains to provide greater flexibility against geopolitical challenges while broadening its manufacturing footprint to locations like India, the UK, and the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LhrKOSZ
via IFTTT

Read More

SC pulls up Centre over soaring medicine costs

The Supreme Court expressed concern over the government's role in allowing steep medicine prices to persist. Justices Vikram Nath and Sandeep Mehta questioned the justification for significant price discrepancies faced by patients. The court highlighted a lack of accountability regarding how drug manufacturers benefit from inflated prices. Government representatives stated that regulatory measures should not encompass the entire drug pricing ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WKD2ST4
via IFTTT

Read More

Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar

Cipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for this drug is expected to expire around 2029, allowing for potential market entry. Cipla anticipates capturing a significant share of this lucrative market segment after the launch. Additionally, the company reported a 35% decline in consolidated net profit in the September quarter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q27gIB0
via IFTTT

Read More

Healthware partners Fujifilm to expand use of precision surgical imaging solutions

Healthware has entered a partnership with Fujifilm to expand the use of intra-operative ultrasound systems across India. This collaboration aims to meet the critical clinical needs in complex surgeries. Real-time surgical ultrasound will be made available in more operating rooms, enhancing the speed of surgical procedures. The partnership combines technological innovation with clinical expertise for better patient outcomes. Healthware's national service and support network will facilitate this advancement in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R63ECuB
via IFTTT

Read More

Cipla expects US business to draw support from upcoming product pipeline

Cipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fell by 19% due to increased competition impacting sales of generic Revlimid. However, Cipla anticipates that its upcoming product pipeline will support performance in North America. In India, domestic revenue rose, providing some resilience amidst challenges in the US market.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/cipla-expects-us-business-to-draw-support-from-upcoming-product-pipeline/articleshow/135229843.cms
via IFTTT

Read More

Sakar Healthcare posts Rs 11 cr profit in Q2

The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrA53o
via IFTTT

Read More

Mankind Pharma shares key business developments from Q2 & H1 of FY27

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8DIvUoX
via IFTTT

Read More

Lord’s Mark Industries Limited becomes Asia’s first company to secure multiple US FDA registrations for 200+ surgical and hygiene products; US exports to begin in December

Silvassa manufacturing expansion completed ahead of schedule as the company prepares to expand its international footprint across the United States and South America

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z25eqPc
via IFTTT

Read More

Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y6PozZ
via IFTTT

Read More

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RCM4mj0
via IFTTT

Read More

One Science Nutrition: Building a science-led approach to sports nutrition

One Science Nutrition was co-founded by Aman and Aniket Vachher to create credible sports nutrition products. The brand aims to cater to evolving consumer expectations around product quality and transparency. Their product range includes various supplements that support diverse fitness goals and health benefits. Future strategies involve leveraging artificial intelligence to enhance consumer experiences and product discovery. The founders emphasize maintaining core values while pursuing growth in the nutrition industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90xr2IG
via IFTTT

Read More

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GY9MseC
via IFTTT

Read More

States urged to enforce ban on reuse of single-use medical devices

The Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some private hospitals have raised concerns regarding patient safety and regulatory compliance. The directive specifically targets misuse in high-stakes medical fields such as cardiology and neurosurgery. Monitoring and enforcement of compliance by healthcare establishments have been mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dTYQWjS
via IFTTT

Read More

Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say

Jubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure and refinance project-related liabilities at overseas subsidiaries. The proposed issuance, rated AA+ by India Ratings, could take place before the end of next month, according to two merchant bankers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5Ax9oDs
via IFTTT

Read More

From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plans

Biodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture will notably elevate its production capacities and diversify its contract development and manufacturing services. Biodeal is committed to fortifying existing partnerships with clients leveraging its innovative nasal and oral drug formulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3u5xN89
via IFTTT

Read More

Cipla subsidiary clears USFDA inspection with zero observations

Cipla on Friday said a routine US Food and Drug Administration (USFDA) inspection at its wholly owned subsidiary InvaGen Pharmaceuticals' manufacturing facility in Hauppauge, Long Island, New York.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BoM65tl
via IFTTT

Read More

At 22, he built a gym machine in his garage. Now, the man behind the ‘Ferrari of fitness’ is looking to India

Technogym founder Nerio Alessandri is looking to expand the Italian fitness and wellness company's presence in India, where fitness facility membership remains below 1% of the population. Founded in 1983, Technogym has grown from a garage startup into a global brand serving athletes, gyms, luxury hotels and households.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH8bJRr
via IFTTT

Read More

Cancer drugs to get cheaper? Here’s what the latest government order says

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7MUrnm
via IFTTT

Read More

From Continuous Data to Trusted Health Intelligence: What Abu Dhabi and India Can Learn From Each Other About Predictive Health?

Predictive health will depend not on how much data health systems collect, but on whether they can validate it, govern it responsibly, and translate it into earlier action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xsof6CR
via IFTTT

Read More

Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in India

Sanofi Healthcare has obtained authorisation from the Central Drugs Standard Control Organisation for Qfitlia. This therapy is designed to prevent bleeding in haemophilia patients aged 12 years and older. Qfitlia offers unique protection for Haemophilia A and B patients, requiring only six injections annually. The approval follows promising results from the ATLAS phase 3 clinical trials. This advancement aims to enhance access to treatment options for patients in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE29pxY
via IFTTT

Read More

Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a combination of toripalimab, cisplatin, and paclitaxel. Approximately 80 percent of esophageal cancer cases in India are attributed to esophageal squamous cell carcinoma. The approval derives from positive results in the Phase 3 JUPITER-06 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72My0Yt
via IFTTT

Read More

HealthRail: Turning India's hospital receivables into growth capital

In a strategic move to streamline hospital cash flow, HealthRail is offering expedited access to accrued revenues. This initiative specifically addresses the payment delays that hospitals experience with insurance providers and public funding programs. By lowering days sales outstanding for qualifying receivables, this system aims to substantially bolster hospitals' liquidity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LBOoExe
via IFTTT

Read More

NATCO Pharma subsidiary launches Carboplatin in US market to address shortages

Indian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market by its American subsidiary. The subsidiary would collaborate in manufacturing with Chennai-based Tero Labs Pvt Ltd. The launch is aimed at meeting the shortage of the drug. Carboplatin is directed towards the treatment of advanced ovarian carcinoma, including first-line combination therapy and palliative treatment of recurrent disease after prior chemotherapy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDpavA1
via IFTTT

Read More

AIIMS doctors identify ‘Red Alert Zone’ to reduce risks in complex cancer surgery

AIIMS doctors have recognized two critical anatomical zones during complex cancer surgeries in women. These zones help reduce bleeding and prevent injuries to vital organs. One zone, known as 'Ray's Zone', is crucial for surgeries involving the pelvic area. The other, 'Ray's Hepatocaval Triangle', assists during liver mobilization near major vessels. Identifying these zones enhances surgical precision and patient outcomes in oncological procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MPDFt6b
via IFTTT

Read More

The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reach

For millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that remain out of reach, the affordability crisis runs deep. A proposed cap may help, but question remains if it will be enough to change the picture.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d2JXKVZ
via IFTTT

Read More

Aayush Wellness launches calcium, vitamin supplements; enters USD 16.3-bn bone & joint health segment

Aayush Wellness Limited has launched Aayush Calcium Vitamin Tablets, expanding its nutraceutical portfolio into the bone and joint health segment. The formulation combines calcium citrate, vitamin D2, magnesium, zinc and folic acid to support bone strength, calcium absorption and musculoskeletal health. The company said the launch aligns with growing consumer interest in preventive healthcare and nutritional supplements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vgTbfzQ
via IFTTT

Read More

NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9

India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. This cap, effective from November 9, applies to all listed drugs, including Atezolizumab and Bevacizumab. Manufacturers must adjust prices if they exceed the newly calculated maximum retail price. Compliance will be monitored by state drug controllers and hospitals, which play a significant role in drug supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ABuEGc
via IFTTT

Read More

Shridevi Institute, US-based Vaxonyx sign MoU for AI-driven cancer and genomic research

Shridevi Institute of Medical Sciences in Tumakuru has signed an MoU with Vaxonyx LLC for collaboration. This partnership aims to focus on AI-enabled bioinformatics and genomic research tailored for Indian populations. They will develop personalized cancer therapies by analyzing individual tumor profiles. The collaboration will also explore the creation of genomic datasets to improve genetic models. Moreover, they intend to develop DNA-based vaccine candidates for relevant public health issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nj7thfi
via IFTTT

Read More

NITI Aayog explores policies to boost India's medical and dental device manufacturing industry

NITI Aayog is exploring policy measures to improve the manufacturing capabilities of medical and dental devices in India. The meeting included domestic manufacturers, government officials, and experts from IIT Delhi and IIT Mumbai. Key challenges such as regulatory hurdles and cost disadvantages faced by Indian manufacturers were discussed extensively. The industry body AiMeD emphasized the need for simpler regulations and financial support for local manufacturers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OU16ieb
via IFTTT

Read More

HLL Lifecare launches eStore to expand direct-to-consumer reach

State-owned company HLL Lifecare launched HLL eStore, a digital platform aimed to expand access to its healthcare and wellness products across the country. The platform would be part of its broader digital transformation strategy, enabling customers, business partners and healthcare institutions to engage with the company through an integrated online marketplace. The eStore also offers medical products and supplies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XZRSFnY
via IFTTT

Read More

AYUSH sees rise in patents filings showcasing innovation growth; 4,077 applications filed from 2014 to 2026

Ayush-related Intellectual Property activity has seen substantial growth, with over 4,000 patent applications from 2014 to 2026. The Ministry of Ayush emphasises the increasing participation of individuals and institutions in this sector. Patent filings peaked post-COVID, reflecting a focus on research and innovation. Natural persons and educational institutions contributed significantly to the total filings and grants. The government continues to foster an enabling environment for traditional knowledge and scientific research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lxD4gmf
via IFTTT

Read More

India needs 2.6 billion sq ft of healthcare space by 2035, says CBRE

India requires an expansion of its healthcare infrastructure with an additional 2.6 billion sq ft by 2035. This need arises due to an expected demand for nearly 2.9 million more hospital beds nationwide. Current statistics show India has only 1.6 hospital beds per 1,000 people, significantly less than the global average. Certain states face much lower hospital bed density compared to their disease burden, indicating unmet healthcare needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rfzT6tg
via IFTTT

Read More

Indian, German firms to collaborate on immunoglobulin products: Indian Embassy

Germany's Neovii Biotech and India's VINS Bioproducts will explore collaboration on manufacturing and commercialising immunoglobulin products, including anti-thymocyte globulin used in organ transplantation and certain blood disorders. Facilitated by the Indian Embassy in Berlin, the agreement involves technology transfer to India and could strengthen domestic capabilities in specialised biological products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VT6fGIw
via IFTTT

Read More

Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch

Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to launch Pebrilzo in early 2027 in the UK and EU, and in late 2028 in the US. In response to Genentech's patent infringement suit, the New Jersey court dismissed the case at Genentech's request. The details of the settlement agreement remain confidential between the companies involved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NhPxSjv
via IFTTT

Read More

Novo Holdings, GIC, Axight look to back AIG Hospitals; Founders aim to pare 10-12% stake at Rs 24,000 cr valuation

Novo Holdings and GIC are discussing investing Rs 2,000-2,500 crore in AIG Hospitals based in Hyderabad. The investment reflects a growing interest among private equity firms in Indian healthcare. Founders of AIG Hospitals, Duvvur Nageshwar Reddy and Penmetsa Venkata Subbaraju, are planning a stake sale. AIG Hospitals has plans for a new facility in Visakhapatnam and aims to grow significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e4M9VTd
via IFTTT

Read More

Health ministry asked to examine coronary stent safety concerns

Cabinet secretariat has directed the Union health ministry to investigate safety issues related to coronary stents. These concerns were raised by Rajya Sabha member Ajeet Madhavrao Gopchade regarding models withdrawn in Sri Lanka. Gopchade emphasized the need for strengthening India's regulatory framework for coronary stents. He called for improved clinical documentation and robust traceability for implanted stents. His representation highlighted the importance of patient follow-up and monitoring of device-related complications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/k5eM81q
via IFTTT

Read More

Biocon clears path for cancer drug launch

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3YycUMS
via IFTTT

Read More

NMC Healthcare founder BR Shetty files $15 billion lawsuit against Bank of Baroda

The suit, filed in the Bombay High Court, seeks $5 billion in direct damages for alleged fraud and negligence, $5 billion in consequential damages and $5 billion in compensation for reputational harm arising from various actions taken by the bank, including a lookout circular issued against him.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WdTHKj
via IFTTT

Read More

Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growth

Kiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need for continued investment in research and regulatory reforms to enhance drug development. The industry must focus on maintaining high-quality standards as it seeks to innovate. Closer cooperation between industry and regulators can help sustain momentum during this transition. India has the potential to participate actively in the global innovation ecosystem.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0UTfv9L
via IFTTT

Read More

Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application

Zydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFDA is expected to complete its review process by the third quarter of 2027. This biosimilar, named FYB206, was developed without a comparative Phase III efficacy trial. Zydus aims to make effective treatments more accessible in the oncology field in North America.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dk6iDnb
via IFTTT

Read More

Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possible

An expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduce drug prices and save patients money. Retail prices of some anti-cancer drugs could drop by up to 70% as a result of this cap. The trade margin rationalisation will apply to all cancer medicines, including branded and generic versions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WohERwL
via IFTTT

Read More

Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicines

The Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning why other vital medications lack similar oversight when sold at exorbitant rates. The Solicitor General emphasized the importance of maintaining a balance between drug availability and market dynamics in determining prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Luz1p5H
via IFTTT

Read More

Joint pain isn’t the same for everyone. Should treatment be?

Joint pain is frequently dismissed as an inevitable consequence of aging; however, it may point to significant underlying issues. Symptoms like stiffness and inflammation warrant a consultation with healthcare professionals. Various forms of arthritis necessitate unique treatment approaches, and symptoms can differ from person to person. Maintaining an active lifestyle and a healthy weight is crucial for preserving joint health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KfBZET3
via IFTTT

Read More

Roche calls for global healthcare overhaul to tackle disease burden

Roche highlights the urgent need for a transformation in global healthcare to effectively tackle chronic diseases. Jorg Rupp pointed out that existing healthcare infrastructures are largely reactive, falling short in proactively addressing the rise of non-communicable diseases. This burgeoning issue not only challenges health systems but also imposes heavy financial demands. Governments must begin viewing healthcare as a crucial investment aimed at enhancing health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQphSg0
via IFTTT

Read More

Tricog Health targets 100 million cardiac screenings by 2030: CEO Dr Charit Bhograj

Bengaluru-based Tricog Health aims to conduct 100 million cardiac screenings by 2030, having screened over 41 million patients since its founding in 2014. The healthtech firm uses AI-enabled ECG devices and specialist reviews to detect heart conditions, with operations across several Indian states and 14 countries. Its technology aims to reduce diagnosis delays and improve early detection of cardiovascular diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fBrLahj
via IFTTT

Read More

Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-Shaw

Biocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push for a shift beyond generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Sm9YKA
via IFTTT

Read More

Health ministry proposes curbs on prescription drug ads by retailers, wholesalers and distributors

The union health ministry has proposed extending advertising restrictions on prescription drugs to retailers and distributors. This change will bar them from advertising certain medicines without prior government approval. The amendment affects drugs covered under Schedules H, H1, and X, which require medical oversight. The existing regulations already apply to pharmaceutical manufacturers. The recommendation for this amendment comes from the Drugs Technical Advisory Board.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FKdI3EX
via IFTTT

Read More

Experiments on animals set to become easier

The Centre plans to significantly change the regulations governing animal experimentation. The proposed rules aim to allow institutional ethics panels to approve most experiments. Currently, only small animal experiments can be approved at the institutional level while larger ones require central oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AKjUpnS
via IFTTT

Read More

Hair fall decoded: Causes, triggers, and warning signs

For many, hair shedding can raise concerns, with various elements at play like stress, hormonal imbalances, and nutrition. Recognizing the difference between shedding and breakage is essential, as each has distinct roots and remedies. Noting specific loss patterns can guide you towards effective treatments. Additionally, seeking expert guidance can shed light on potential health issues impacting your hair's condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L1l56pJ
via IFTTT

Read More

National Medical Commission bans doctors & hospitals from using AI-generated patient testimonials, fake cure claims in medical ads

The National Medical Commission has implemented new ethical advertising guidelines affecting doctors and hospitals. These guidelines prohibit the use of artificial intelligence for generating promotional content or testimonials. Measures have also been taken to restrict paid patient solicitation and misleading claims in advertisements. Strict penalties have been established for non-compliance, including warnings and license suspensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GCsa0t7
via IFTTT

Read More

Govt set to cap trade margins on more cancer drugs before SC hearing

The Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda will make the announcement just ahead of a Supreme Court hearing on October 12. This decision comes after concerns regarding the price gap between retailer prices and MRP of some cancer medications. Trade margins were capped previously, leading to significant price reductions on several anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WawMSEi
via IFTTT

Read More

Supreme Court seeks committee to curb pharma firms’ unethical marketing practices

The Supreme Court has directed the government to form a committee regarding pharmaceutical marketing regulations. This follows concerns over unethical practices influencing doctors’ prescribing decisions and patient health outcomes. Petitioners are advocating for stronger legal frameworks beyond the current voluntary code. They emphasize the need for a statutory code supported by penalties to protect the right to health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OuafslW
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8vEpzIN
via IFTTT

Read More

The 30-Minute Medicine Problem

How India's largest ePharmacy is building an in-house quick-commerce engine across cities and why moving medicines in under an hour is far more complicated than it looks

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c4NTo3D
via IFTTT

Read More

Drug panel rejects child images on cough syrup labels, proposes age warning for use below 4 years

Cough syrup bottles will soon include a prominent red warning stating their use is not recommended for children under four. An expert committee rejected child-oriented imagery on labels, which could imply suitability for young children. This decision follows ongoing concerns about the safety of cough syrups in pediatric care. The proposed change aims to prevent confusion regarding age restrictions for these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BwgnLQy
via IFTTT

Read More

Lord’s Mark strengthens UK and UK allied market strategy with regulatory backing for IVD portfolio.

In an exciting development, Lord's Mark Industries has secured registration for its In-Vitro Diagnostic portfolio with the MHRA, significantly boosting market access. This follows the approval of their AI-enhanced Renalyx haemodialysis system in the UK. The firm aims for a December 2026 market launch for its IVD products, ahead of schedule, along with a planned January 2027 start for its pathology lab, highlighting its strong commitment to global healthcare integration.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hoce1DA
via IFTTT

Read More

Centre may seek legal view on licensing of sterile drugs

The government is actively exploring a proposal to expand central licensing authority over all sterile drug products following a recent Supreme Court decision that restricted the enforcement authority of central officials. A meeting of the drugs consultative committee underscored the essential requirement for specialized regulatory oversight for these sensitive products, aiming for uniform regulations. A dedicated sub-committee will evaluate the proposal's feasibility and gather legal insights before any definitive actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6l2iYZ
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zRjr0f8
via IFTTT

Read More

Wall Street’s $10 billion India hospital bet sparks a fight over bills

Wall Street has poured about $10 billion into Indian hospital chains over the past five years, with investors including Blackstone, KKR, TPG and General Atlantic betting on India’s huge shortage of hospital beds and rising demand for specialised care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W2kVamB
via IFTTT

Read More

Robotic surgery gains rapid ground in India, Delhi NCR leads: Experts

India is rapidly scaling up robotic surgery, with procedures rising from 8,912 in 2021 to 44,857 in 2025, while Delhi NCR has emerged as the country’s biggest hub with 39 hospitals using robotic systems. Experts say the next phase could include wider use of telesurgery, remote mentoring and access to specialist care beyond major cities, subject to regulatory and cybersecurity safeguards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EZDxXmd
via IFTTT

Read More

Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims

Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwzvNLP
via IFTTT

Read More

India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO

Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v7L6naV
via IFTTT

Read More

‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s7BoJzj
via IFTTT

Read More

Karnataka flags 52x mark-up on cancer drugs, seeks Centre's intervention

Karnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs and medical devices. The state government has urged the Centre to implement transparency in pricing and regulate trade margins for essential medicines. Mark-ups observed ranged from 10 to over 52 times the actual procurement costs for various items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xKPHXfq
via IFTTT

Read More

Rasayan Labs launches AI-native drug discovery platform at ICT Mumbai

In an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discovery initiatives. This innovative platform merges critical functions, including retrosynthesis and ADMET prediction, to optimize research efficiency. Free access will be granted to researchers at the Institute of Chemical Technology, marking a pivotal collaboration that seeks to dramatically reduce drug development timelines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KhXkoyt
via IFTTT

Read More

From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CkebFWv
via IFTTT

Read More

Lord’s Mark secures MHRA registration for dialysis device, plans UK expansion

Lord's Mark Industries Limited has successfully secured regulatory registration from the MHRA for its innovative haemodialysis machine, paving the way for its expansion in the UK's healthcare technology sector. With plans to commence exports in January 2027 and potentially establish its own dialysis centres, this milestone signifies a crucial step towards creating a comprehensive renal-care ecosystem, manufactured by Renalyx Health Systems Pvt. Ltd. for both institutional and home usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yfeC9vG
via IFTTT

Read More

ChrysCapital to take minority stake in Linux laboratories

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involves both primary capital and a secondary purchase, marking Tata Capital Healthcare Fund II's full exit. The funding will help Linux deepen its presence in existing specialties and expand into new therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RybAXgJ
via IFTTT

Read More

Sun Pharma plans $1 billion local debt sale for loan takeout, sources say

Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is expected to issue two-, three- and four-year bonds as Indian companies increasingly turn to domestic debt amid high US borrowing costs and expectations of an RBI rate hike.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rh4Cyg
via IFTTT

Read More

SC draws the line on Fortis audit, says no ‘fishing and roving’ probe into banks

The Supreme Court clarified the forensic audit's focus is on Fortis Healthcare Holdings Private Limited and the Singh Brothers. This audit is not a broad inquiry into the dealings of other banks. The court highlighted the audit relates specifically to transactions between FHHPL, FHL, and banks involved. The clarification came in response to a prior ruling by the Delhi High Court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eLn10bd
via IFTTT

Read More

Kerala HC says exorbitant drug prices can trigger government intervention in patented medicines

The Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the Centre to gather data on the affordability of specific life-saving drugs. This ruling addresses access issues for two breast cancer medications, abemaciclib and ribociclib. The decision empowers the government to consider invoking Section 100 of the Patents Act for affordable access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kNIEnjZ
via IFTTT

Read More

Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9

Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YrEHkSp
via IFTTT

Read More

Govt, private hospitals likely to be graded on quality & safety

Niti Aayog is developing a national quality framework for public and private hospitals, aligned with international standards, to help patients compare hospitals and improve healthcare quality. The framework will include patient safety, clinical outcomes, readmission rates, medication errors and specialty-specific indicators such as survival and mortality rates.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRmPYG1
via IFTTT

Read More

CDSCO steps up scrutiny of pharma drugs containing narcotic substances

The Central Drugs Standard Control Organisation is addressing regulatory gaps related to the illegal diversion of pharmaceutical drugs. Following the National Committee for Coordination on Drug Trafficking meeting, specific targets have been assigned to CDSCO. The drugs consultative committee will examine current regulations to recommend improvements. Union home minister Amit Shah emphasized the need for a coordinated strategy against evolving drug trafficking.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3KmoGR
via IFTTT

Read More

Fortis Healthcare confident forensic audit will clear company in share transfer dispute

Fortis Healthcare has expressed confidence that a forensic audit will verify its non-involvement in a share transfer dispute. The Supreme Court's recent ruling allows the audit to proceed while minimizing the influence of previous judgments. Fortis clarified that it was never a party to the arbitration between the Singh Brothers and Daiichi Sankyo.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oL67Mlu
via IFTTT

Read More

Fortis defends itself after Supreme Court allows forensic audit, says it was "complete stranger" to Daiichi-Singh Brothers dispute

In a disclosure to the stock exchanges, Fortis said the Supreme Court, in its September 25 order, disposed of the company's Special Leave Petition challenging the Delhi High Court's August 31 order directing a forensic audit of the company in the matter of Daiichi Sankyo Company Limited vs. Malvinder Mohan Singh & Ors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kF1jaJZ
via IFTTT

Read More

Ayush services sector growing fast; projected to hit up to USD 318 billion by 2047: Study

The Ayush services sector is projected to reach USD 216-318 billion by 2047 as it continues to expand. This sector reported a 16.91 percent compound annual growth rate since 2022-23 and supported 1.76 million livelihoods. Clinics and day-care centers generated the majority of the sector's revenue, with Ayurveda leading individual systems. The sector's role in Medical Value Travel is also notable with international patients contributing substantially to revenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30xLvPX
via IFTTT

Read More

India needs five-year policy to make precision cancer care afforable, says expert

India needs a five-year roadmap to expand access to genomic testing and targeted cancer therapies for lower-income patients, oncologist Dr Bhawna Sirohi said. A member of the new Lancet Oncology Commission on precision cancer, Sirohi flagged high testing and drug costs and urged their integration into public healthcare schemes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw9NSF2
via IFTTT

Read More

Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yJxf8Zh
via IFTTT

Read More

SC clears forensic audit of Fortis-IHH deal involving erstwhile Religare promoters Singh brothers

The Supreme Court has cleared the way for a Delhi High Court-appointed forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and entities linked to former promoters Malvinder and Shivinder Singh. The audit will trace assets linked to the brothers and examine the dilution of their Fortis shareholding.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8TvcrQx
via IFTTT

Read More

Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit

The Supreme Court has declined to interfere with Delhi High Court orders in the long-running Daiichi Sankyo-Fortis dispute, allowing a forensic audit to proceed as part of efforts to trace assets linked to enforcement of a 2016 arbitral award against former Fortis promoters. The apex court did not examine the merits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsfkSCY
via IFTTT

Read More

Alkem Laboratories CFO Nitin Agrawal resigns

Alkem Laboratories CFO and Key Managerial Personnel Nitin Agrawal has resigned from the drug maker to pursue new professional opportunities, the company said in a regulatory filing. Agrawal will step down from his senior management position effective September 30, 2026. He cited long-term professional and personal growth in his resignation letter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WQ9gku1
via IFTTT

Read More

HLL Lifecare to expand pharmacy network to 600 outlets, add 4,500 jobs

HLL Lifecare Ltd intends to broaden its pharmacy network to 600 outlets nationwide over the coming year, creating around 4,500 job opportunities in healthcare. With around 340 existing stores, HLL champions affordable healthcare solutions while ensuring vital services reach all citizens. Notably, this expansion will roll out just in time for World Pharmacists Day on September 25.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QnXliu9
via IFTTT

Read More

Goldman Sachs picks up stake in Lord’s Mark Industries Limited

Lord’s Mark Industries Limited has garnered impressive interest from investors following the sale of approximately 1 crore shares by its promoter. This strategic move was intended to meet SEBI’s Minimum Public Shareholding norms, boosting the company’s visibility in the market. Prominent investors like Goldman Sachs Investments Mauritius I and AT Trade Overseas took part in this endeavor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PLw2EHT
via IFTTT

Read More

Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil Patel

Zydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to focus on specialty medicines and biotechnology innovation. It aims to achieve double-digit revenue growth and improved profitability over the next five years. Zydus intends to enhance its oncology franchise and explore partnerships for novel biologics. The expected contributions from discovery-led products will materialize from 2030 onwards, strengthening its market position.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NYwr5pR
via IFTTT

Read More

Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD

"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business and Saroglitazar and maybe something more as well. In the next four to five years we will definitely see meaningful value being created from these."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e0dODfu
via IFTTT

Read More

How India’s smaller hospitals are becoming the next big digital health market

Smaller hospitals in India are becoming the new digital health market. As the Ayushman Bharat Digital Mission expands, the demand for digital solutions had increased. Healthcare tech companies are focusing on providing solutions tailored to smaller providers. Despite challenges in implementation, the integration into existing workflows could improve patient experiences significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uz3Gadq
via IFTTT

Read More

Pfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priority

Pfizer India has stated that patient safety and product quality are their top priorities following FDA actions. The Karnataka FDA canceled 16 drug licenses and suspended eight others due to counterfeit drugs. A raid uncovered an illegal operation repacking low-cost medicines as branded drugs, particularly Pfizer products. Pfizer has removed affected batches from the market and is cooperating with authorities in the investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/owXUsIV
via IFTTT

Read More

Ozempic maker Novo Nordisk sets sights on hair-loss market

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7nF6lZ
via IFTTT

Read More

Root of the matter: What to know before trying professional hair treatments

Professional hair treatments can deliver smoother, shinier and more manageable hair, but their effects and risks vary depending on the treatment, formulation and existing hair health. This article explains how treatments such as keratin, relaxers and hair botox work, key questions to ask before a salon treatment, potential risks and why maintaining overall hair and scalp health matters beyond cosmetic results.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YEZ4asr
via IFTTT

Read More

Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next

Bharat Biotech is “back in action” after a two-year post-Covid reset, founder Krishna Ella says, with the company expanding beyond vaccines into cell and gene therapy and monoclonal antibodies. The vaccine maker is advancing programmes for TB, Nipah, Ebola, chikungunya, malaria, Zika and antimicrobial resistance, while exploring an IPO to fund new therapies and potential acquisitions. Ella says the company, which currently has around Rs 2,000 crore in revenue and is debt-free, is focused on accelerating innovation and preparing the next generation to lead its human and veterinary businesses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/py9TwbP
via IFTTT

Read More

Medical device rules may get tougher: Govt plans new powers to stop manufacture, sale of unsafe, defective and spurious products, order destruction

The government is considering tougher medical device rules that could give regulators explicit powers to stop the manufacture, sale or distribution of unsafe, defective, substandard or spurious products and order their destruction. The proposed amendment to Rule 30(1) of the Medical Devices Rules, 2017, is aimed at strengthening enforcement, reducing ambiguity and ensuring potentially harmful devices are removed from circulation more quickly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ONHaMD
via IFTTT

Read More

Ichor Biologics seeks $80-100 million PE funding for minority stake sale

Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the specialized plasmatherapy segment. Promoters Ananda Reddy Sudini and Sujana Sudini hold significant stakes in the firm. Ichor manufactures therapeutic protein products derived from human plasma. The company's products serve various critical therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dLQtXB1
via IFTTT

Read More

Unify Group marks ten years of success with The Grand Gala

Celebrating a decade of excellence, Unify Group hosted an impressive gala event that showcased its remarkable journey since its inception in 2016. Initially rooted in healthcare, the organization has boldly ventured into travel, logistics, and technology, paving the way for future innovations. The evening was a tribute to their significant milestones and a look ahead at the blossoming opportunities in their expanding portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XlzQewb
via IFTTT

Read More

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation across the EU.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8XivGI1
via IFTTT

Read More

Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacity

Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LxkSpVN
via IFTTT

Read More

Karnataka medical institute opened by PM plans free cancer immunotherapy for patients

The Sri Madhusudan Sai Institute plans to offer free immunotherapy for cancer patients. A new 600-bed hospital will soon launch on campus, expanding free medical services. Modern genomics treatment is already initiated, and rare disease research is underway. The mission has invested significantly in service initiatives and seeks corporate and international support. Free paediatric healthcare and nutrition programs are also highlighted as key achievements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jH0WehJ
via IFTTT

Read More

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger scientific evidence and safety monitoring for wider adoption. The Central Council for Research in Ayurvedic Sciences stressed this at a symposium. Discussions focused on safety and evidence-based care for non-communicable diseases. The council highlighted its work in public health and traditional medicine. Strengthening pharmacovigilance is crucial for patient safety in Ayurveda.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYGD7aX
via IFTTT

Read More

ENTOD Pharmaceuticals secures patent for its insulin eye drop

Currently at the pre-clinical stage of development, the patented insulin eye drops are being investigated as a potential novel therapeutic approach to address unmet needs in ophthalmic care, the Mumbai-based company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IVdDPMv
via IFTTT

Read More

When doctor is at home: Technology enables 24x7 monitoring beyond hospital

A new technology offers continuous remote health monitoring for patients at home. This system helps individuals recovering from surgery and the elderly stay supervised. Patients receive regular check-ins and immediate advice for any health abnormalities. The technology uses biosensors to track vital signs and prevent emergencies. This innovation provides reassurance and timely medical support for many individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PyEDvtO
via IFTTT

Read More

Drugs Panel to weigh bringing all sterile drug products under central licensing amid contamination concerns

A proposal will soon be considered to centralize licensing for all sterile drug products. This move aims to tighten regulations on medicines prone to microbial contamination. Currently, only specific sterile medicines fall under central licensing authority. The proposal highlights fragmented existing frameworks and varying state inspection practices. Bringing all sterile products under central oversight will create a uniform regulatory system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUrDiCs
via IFTTT

Read More

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGtOv2Z
via IFTTT

Read More

Health ministry issues advisory against unregulated stem cell therapies, restricts autism treatment to approved clinical trials

The Union health ministry issued an advisory against unregulated stem cell therapies. Therapeutic use of stem cells for autism is restricted to approved clinical trials. This advisory reiterates the existing framework governing stem cell research and therapy. It aligns with a Supreme Court ruling restricting unproven stem cell treatments. States and union territories must ensure strict compliance with the applicable framework.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/invwzoN
via IFTTT

Read More

Can wearable tech ease period pain? Curapod launches new device

Curapod has launched a new wearable device for menstrual pain management. This device utilizes red and near-infrared light wavelengths for pain relief. The wearable connects to a mobile application for personalized light dosage adjustments. Clinical evaluations indicate significant pain reduction for many users. The company is expanding its wearable technology into other pain management areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYaf8nh
via IFTTT

Read More

Centre seeks NPPA report on high markups in hospital consumables

The Centre has requested a report from the NPPA regarding price discrepancies. Maharashtra FDA flagged significant gaps between trade prices and MRPs for hospital items. A survey revealed markups of over 2,800 percent on certain medical consumables. This situation may revive discussions on trade margin rationalisation for medical devices. The medical device industry supports calls for fair pricing and ethical practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tIavsxu
via IFTTT

Read More

US names India, China, Pakistan among drug transit, illicit drug-producing nations for FY27

The United States has designated India, China, and Pakistan as major drug producing or transit countries. This presidential determination covers twenty-three nations for fiscal year twenty twenty-seven. Afghanistan, Bolivia, Burma, and Colombia were separately identified for failing counternarcotics obligations. Inclusion on the list considers geographic and economic factors for drug production and transport. This designation does not necessarily reflect current government efforts or US cooperation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UOjoGXe
via IFTTT

Read More

Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT

Read More

Centre proposes easier norms for faster drug rollout

India's government plans to streamline drug approval processes for domestic use. Applicants can now start studies after intimating the drug regulator. Import license processing timelines for new drugs will be halved to forty-five days. This move aims to improve the ease of doing business in the sector. However, certain high-risk drug categories will retain existing stringent requirements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cMTsGlP
via IFTTT

Read More

New TB vaccines expected from 2029 could prevent 7.3 million deaths by 2050, Gavi says

By 2029, new tuberculosis vaccines are expected to save more than seven million lives, emerging as a crucial element for global health improvement. Ensuring a steady supply for the countries most affected by the disease is essential. Additionally, these vaccines may provide considerable economic advantages for developing nations. Gavi aims to promote timely accessibility and widespread distribution of these immunizations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y8JHTRa
via IFTTT

Read More

Ayurveda eyes global growth as research, innovation reshape traditional system

Ayurveda is gaining global relevance through research and innovation. Growing interest in holistic healthcare creates new international opportunities for this system. India's Ayush market has seen significant economic growth in recent years. The government promotes Ayush-based medical travel and introduced a dedicated visa. Ayurveda's future international success depends on evidence and standardized practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irgcVF9
via IFTTT

Read More

Manipal Hospitals scouts for acquisitions in Andhra, Keralam, Delhi-NCR; bets on AI-led healthcare

Manipal Health Enterprises plans significant expansion across several Indian states. The company is adopting a digital-physical healthcare model driven by Artificial Intelligence. Strategic acquisitions and a new greenfield project in Mumbai are underway. Investments focus on AI-enabled nursing and patient monitoring systems. The healthcare major aims to add over 2,400 beds by the year 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALijwlZ
via IFTTT

Read More

AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT

Read More

Imported dialysis solution fails endotoxin test in Himachal; lab flags nine regulatory violations

A Himachal Pradesh government drug laboratory has declared two batches of an imported peritoneal dialysis solution “Not of Standard Quality” after they failed bacterial endotoxin tests. The report also flagged nine regulatory violations, including use of non-Indian pharmacopoeial standards, labelling deficiencies, missing safety warnings and inadequate importer details.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbDLdI7
via IFTTT

Read More

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administration with flying colors. Conducted from August 31 to September 10, 2026, the inspection resulted in zero observations, leading to a clean report from the USFDA and highlighting the facility's commitment to excellence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6w7jzn
via IFTTT

Read More

India crosses 80 lakh HPV vaccinations in nationwide cervical cancer prevention drive

India has now administered over 80 lakh HPV vaccinations to girls. This significant milestone strengthens preventive healthcare and protection against HPV infection. The nationwide campaign, launched in February, targets fourteen-year-old girls for free vaccination. The Gardasil-4 vaccine is available at government health facilities across the country. Parental consent is mandatory for this voluntary immunization program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FGjfMd7
via IFTTT

Read More

Marengo Asia Hospitals raises Rs 400 crore from LeapFrog Investments

Marengo Asia Hospitals has secured Rs. 400 crore funding from LeapFrog Investments. This capital will fuel expansion into tier one and two Indian cities. The company plans to double its hospital bed capacity to 4,000 beds. Marengo Asia Hospitals aims to consolidate its leadership and enter new geographies. This investment reinforces LeapFrog's commitment to healthcare platforms across Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnosAqO
via IFTTT

Read More

iKure bags USD 1.8 Million from global investors to expand primary healthcare in India

iKure Techsoft has successfully raised USD 1.8 million in Pre-Series A funding. This infusion of capital is set to bolster its frontline healthcare workforce and enhance infrastructure, while also advancing its digital health platform through AI integration. iKure aims to provide ongoing care to patients, ensuring access to vital healthcare services for underserved communities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9XYpLUM
via IFTTT

Read More

Regional healthcare hubs emerge as new investment hotspots

Investment is shifting to regional hospital hubs like Jaipur and Vadodara. These markets offer growth opportunities and lower operating costs for investors. Health insurance penetration is also increasing significantly in these areas. Single-specialty segments like IVF and mother-child care are driving deal activity. Regional hospital brands are expected to scale through clusters and strengthen networks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Dr5QALi
via IFTTT

Read More

WHO chief meets JP Nadda, praises India's health gains in maternal, child care and TB fight

WHO chief Tedros Adhanom Ghebreyesus praised India's health sector progress. He highlighted advancements in maternal and child health initiatives. India's Ayushman Arogya Mandirs bring health screenings closer to communities. ASHA workers support mothers and children from conception through adolescence. Discussions also covered India's efforts to end tuberculosis and strengthen regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xF7adih
via IFTTT

Read More

Sun Pharma incorporates global treasury arm at IFSC, GIFT City

On September 8, 2026, Sun Pharmaceutical Industries Ltd announced the establishment of its new subsidiary, Sun Pharma Global Treasury Centre IFSC Ltd. Located in Gujarat's GIFT City, Gandhinagar, this wholly-owned indirect unit has seen an investment of around Rs 9.50 crore in its equity share capital. The company is currently awaiting necessary approvals from the International Financial Services Centres Authority to commence its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ENqUfp3
via IFTTT

Read More

Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters

A recent study suggests Tylenol use by mothers during pregnancy may affect infant reproductive organ development. Researchers observed smaller ovaries and uteruses in three-month-old girls exposed to the drug. This exposure was also linked to fewer ovarian follicles and lower reproductive hormone levels. Long-term follow-up is needed to determine implications for future fertility and menopause timing. Current guidelines still recommend Tylenol as safe for pregnancy pain and fever relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RqiEfv6
via IFTTT

Read More

Government panel plans to retain rule allowing doorstep drug delivery

A government sub-committee has decided to uphold the 2020 rule for doorstep delivery of medicines, recognizing its critical importance for elderly patients and those living in remote locations. Despite the chemists' request to revoke the rule due to concerns of misuse by digital platforms, the sub-committee concluded that maintaining this service is essential for vulnerable populations, recommending instead a stricter enforcement of the existing regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jzdx9C8
via IFTTT

Read More

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This strategic move will enhance Sun Pharma's scale and geographic reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mpojfhz
via IFTTT

Read More

Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to improve accessibility to critical cancer therapies while fostering local industry growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/75cGBLe
via IFTTT

Read More

Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal

The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology partnerships and joint ventures. India aims to become a global hub for medical innovation and device development. Hospitals must offer transparent treatment packages and ethical patient care practices. Enhancing interpreter services will improve foreign patient confidence and communication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zIGLUJt
via IFTTT

Read More

Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TNo8DCW
via IFTTT

Read More

'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch

Indian Immunologicals confirmed no counterfeit Abhayrab vaccine batch was exported. Four individuals were arrested by Delhi Police after seizing fake vaccine vials. The manufacturer stated all vaccine batches undergo independent testing and government certification. This ensures vaccines reach patients through regulated and authorized supply chains. Previous counterfeit batches had triggered international health authority alerts for travelers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/njKqvM9
via IFTTT

Read More

Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal

Piyush Goyal emphasized the importance of enhancing India's pharmaceutical industry to draw in more investments. He urged for the creation of robust supply chains to avoid reliance on a single country. The minister also championed the idea of bolstering research and development, securing patents for Indian innovations, and promoting alignment with global regulatory standards. Furthermore, he recommended increasing production in the Ayush sector and medical devices to achieve global recognition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uSMw7cZ
via IFTTT

Read More

Growing peptide trend raises safety concerns among doctors

Doctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines differ from experimental compounds promoted online. Social media influencers and wellness trends encourage experimentation with unapproved injectable peptides. Experts emphasize that "peptide" is a chemical category, not a safety guarantee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH5JXIE
via IFTTT

Read More

RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities

RPG Life Sciences plans to deploy Rs 500 crore over the next 12 months to expand manufacturing and API capabilities through strategic acquisitions, Managing Director Ashok Nair said. The drugmaker has committed Rs 700 crore for expansion and targets Rs 2,000-2,500 crore revenue by 2030, supported by domestic and international growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JQC9k2U
via IFTTT

Read More

Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets

Novartis India plans acquisitions and deeper market penetration for future growth. The company will focus on five key therapy areas for expansion. Established brands will be brought under full commercial control by 2026-27. Rising chronic diseases and an aging population drive sustained therapy demand. Improved insurance and healthcare infrastructure will unlock new patient demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lN0ugx3
via IFTTT

Read More

Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited

Indian Immunologicals Limited has asserted that the rabies vaccine vials in question were not produced by their facility. Following a potency test failure, a batch was labeled substandard by the drug regulator. IIL emphasized that the Central Drugs Laboratory in Kasauli had assessed and approved the batch. The company identified seventeen discrepancies between the seized vials and their retention samples.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LFCcRA5
via IFTTT

Read More

Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows

India's drug regulator has flagged a batch of Abhayrab rabies vaccine as substandard. This finding marks the second time concerns have been raised about counterfeit Abhayrab doses. The government's Central Drugs Laboratory found the vaccine did not meet potency requirements. Significant differences were noted between the sampled product and a reference sample. The regulator is investigating whether the vaccine is spurious under Indian law.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WJKZFAz
via IFTTT

Read More

Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr

Union (Mauritius) Holdings acquired a 0.57 percent stake for Rs 350.34 crore. This acquisition increased the Moopen family's total shareholding to approximately 24.58 percent. The transaction involved purchasing equity shares from Centella Mauritius Holdings Ltd. The deal was executed at a price of Rs 760 per share on September 2. Aster DM Quality Care now operates a network of 39 hospitals across 28 cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j6mh1zy
via IFTTT

Read More

Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TJnt7ON
via IFTTT

Read More

Drug cos refuse to take sole responsibility for overpricing

Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9slboD
via IFTTT

Read More

Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio

Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j7mLd9n
via IFTTT

Read More

Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD

Max Healthcare plans to expand its bed capacity to ten thousand beds. This significant expansion will involve an investment of approximately six thousand two hundred crore rupees. The company's growth is driven by increasing domestic demand and India's medical tourism prominence. Medical tourism currently represents nine percent of the company's overall business operations. This strategic move aims to address the growing healthcare needs across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4a5D6lo
via IFTTT

Read More

RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs 135 cr

RPG Active Pharma is acquiring Raghava Life Sciences' API and intermediates business. This strategic move aims to strengthen its integrated API play and manufacturing footprint. The acquisition includes twenty-two commercialized APIs and seven development-stage assets. This transaction will be executed on a going-concern basis through a slump sale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OgsZw8E
via IFTTT

Read More

Monsoon illnesses & flu surge lift drug demand

Monsoon illnesses and a significant rise in H1N1 cases are driving a surge in demand for acute therapies and flu vaccines. Sales of anti-infectives and antibacterials saw a 12% month-on-month increase in July, with flu vaccine sales nearly tripling year-on-year in August, leading to supply challenges in several cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ak4YGcN
via IFTTT

Read More

Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company's US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma's investment in the American market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72ErY3T
via IFTTT

Read More

Permira to buy 25.71% in Cloudnine Hospitals parent: CCI filing

Permira, a leading global private equity firm, is ready to buy a significant stake in Cloudnine Hospitals, which places the parent company's valuation at approximately eleven thousand crore rupees. This acquisition involves purchasing the stake from existing investor True North Capital. The deal awaits appropriate regulatory clearances, and Cloudnine is also exploring acquisitions of further hospital ventures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gIk8GKT
via IFTTT

Read More

Sun Pharma to extend MFN pricing to US state Medicaid programmes

Sun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Recent US launches include Leqselvi for severe alopecia areata and Unloxcyt for advanced cutaneous squamous cell carcinoma, strengthening its presence in dermatology and cutaneous oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4aMSKxO
via IFTTT

Read More

Delhi HC orders forensic audit of Fortis, Singh brothers' Rs 4,666-crore trail

The Delhi High Court ordered a forensic audit of Fortis Healthcare transactions. This audit will examine dealings with IHH Healthcare Berhad and RHT Health Trust. It will also probe transactions involving the Singh brothers and Religare Group companies. The court seeks to trace the movement of shares and funds. This comprehensive audit must be completed within six months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QbyhGro
via IFTTT

Read More

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These initiatives aim to reduce reliance on foreign suppliers and lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WK9DlJh
via IFTTT

Read More

Zydus’ Saroglitazar meets primary goal in global Phase II(b) MASH trial

Zydus Lifesciences said its drug Saroglitazar Magnesium met the primary goal of a global Phase II(b) trial for MASH, a serious liver disease linked to metabolic disorders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6rsDj4
via IFTTT

Read More

India seeks easier pharma access in Brazil, pushes to expand Mercosur trade pact

India seeks predictable regulations and easier market access for its pharmaceutical products. Discussions occurred at the India-Brazil Trade Monitoring Mechanism meeting in Brasilia. Both nations aim to expand the existing India-Mercosur trade agreement soon. Bilateral trade between India and Brazil is targeted to reach thirty billion dollars. This move aims to deepen economic ties and expand India's Latin American market presence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/61n5FEv
via IFTTT

Read More

Healthcare ranks second in private credit deals as domestic funds dominate in H1 2026: EY report

India’s private credit market deployed $3.5 billion across more than 100 deals in H1 2026, broadly unchanged from $3.4 billion in H2 2025, according to EY.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QVWef32
via IFTTT

Read More

Jharkhand on high alert over Swine Flu; Health Minister directs hospitals to reserve beds, ramp up surveillance

Jharkhand Health Department is on high alert for potential H1N1 cases. Health Minister Irfan Ansari directed enhanced surveillance and hospital preparedness across the state. Ten additional beds are reserved in all medical college and district hospitals. Monitoring of Influenza-Like Illness and Severe Acute Respiratory Infection cases is intensified. Health teams will screen individuals at major transit points for immediate care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EIXoHG0
via IFTTT

Read More

Park Medi World to expand hospital network across north India, add 1,450 beds by FY28

Park Medi World plans to add 1,450 beds by FY28, expanding its northern India network. The hospital chain focuses on Tier 1, 2, and 3 cities for efficient scaling. Acquisitions will target hospitals with 200-250 beds, expandable to 350. The company reported record net profit and revenue in FY26. Park Medi World is also adopting cleaner energy systems across its facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/M7wtTK1
via IFTTT

Read More

Amrutanjan Health plans to set up 1 lakh direct chemist outlets in FY27

Amrutanjan Health Care plans to establish one lakh direct chemist outlets this fiscal year. The company achieved strong growth in pain management and women's hygiene categories during FY26. This expansion aims to increase brand availability beyond its traditional strongholds in the south and east. Amrutanjan also intends to relaunch its congestion-relief brand, Relief, in the current year. The company remains confident about demand in FY27, supported by its product portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iVRtT8w
via IFTTT

Read More

Is longevity the new flex? Why the new wellness status game is all about health data

Wellness has shifted from luxury retreats to daily personal management and longevity. Wearable technology now tracks health markers, encouraging consistent self-care habits. Fitness goals are increasingly performance-driven, moving beyond aesthetics and appearance. Nervous system regulation through breathwork and sound baths is gaining prominence. This new focus emphasizes consistent, unglamorous daily habits for long-term health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DMfNSWG
via IFTTT

Read More

Cipla Pharma license cancellation: FDA withdraws order after HC raps it for going 'overboard'

Maharashtra FDA withdrew its order to cancel Cipla Pharma's drug sale license after court intervention. The Bombay High Court criticized the regulator for acting in a high-handed and overboard manner. The FDA will now issue a fresh show cause notice to the company for a reasoned order. This action followed alleged irregularities in packaging, storage, and recall of specific tablets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8RsXVBK
via IFTTT

Read More

Drugmakers may bear sole responsibility for overpricing essential medicines under NPPA proposal

The National Pharmaceutical Pricing Authority aims to hold drug manufacturers solely accountable for the excessive pricing of essential medications. This initiative could shield retail chemists and hospitals from legal repercussions concerning pricing infractions. Manufacturers are likely to challenge the proposal, alleging it is uncompromising and unjust. Previously, substantial penalties have been levied against drugmakers for such transgressions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jwgi9SV
via IFTTT

Read More

Jubilant Generics receives show-cause notice demanding over Rs 105 cr

Jubilant Generics received a Rs 105.5 crore GST show-cause notice from Uttarakhand authorities. The notice alleges improper availment of tax refund and Advance Authorisation Scheme benefits. This action pertains to the fiscal years 2020-21 and 2021-22. The company plans to contest the notice and file a detailed reply soon. Jubilant Pharmova expects no significant financial or operational impact.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m9k6XZl
via IFTTT

Read More

Yatharth Hospitals draws interest from Aster, Advent as healthcare consolidation heats up

Aster DM Quality Care is negotiating to acquire a controlling stake in Yatharth Hospitals. This potential acquisition aims to consolidate the hospital sector amid private equity interest. Yatharth Hospitals' stock has seen a significant rise in anticipation of a potential trade. The deal would trigger an open offer for additional shares, expanding the acquirer's ownership. This move would significantly strengthen Aster DM Quality Care's presence in northern India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kn6AYql
via IFTTT

Read More

Demand for vaccines surges as H1N1, other influenza cases see a sharp rise

Demand for flu vaccines has significantly increased this year. At-home vaccination services are seeing a substantial rise in bookings. Rapid testing requests are also growing from various Indian cities. This surge is driven by elevated viral spread and increased awareness. Experts recommend annual vaccinations and usual protective measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JLdDf1V
via IFTTT

Read More

Convening India's brightest minds: The Bharat Life Sciences Award’s Innovation Summit to spotlight life sciences

India sets its sights on becoming a frontrunner in innovation within the life sciences arena. The Bharat Life Sciences Award 2026 aims to honor exceptional scientific achievements while promoting teamwork. With leaders gathering to enhance manufacturing and drug discovery capabilities, discussions will delve into topics like AI-driven discovery and cutting-edge vaccine technologies, ultimately aiming to define the future of India's life sciences landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sDSRyfQ
via IFTTT

Read More

Piramal Alternatives invests Rs 215 crore in Kolors Healthcare

Kolors plans to use the latest capital infusion to strengthen its regional footprint while expanding into additional segments of the wellness and preventive healthcare market. The company also plans to implement its "Kolors 2.0" initiative, which involves a broader transformation of its centres and operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C3n1Nld
via IFTTT

Read More

Kedaara pumps $200m into ortho support wear maker Tynor

Kedaara Capital has acquired a majority stake in Tynor Orthotics for approximately $200 million. This significant deal provides an exit for investor Lighthouse Funds from the medical device maker. Tynor Orthotics manufactures orthopaedic supports and mobility aids for global markets. The company has an extensive distribution network reaching numerous retail outlets and hospitals. Kedaara will partner with Tynor's promoters and its existing strategic partner Thuasne.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c3aRA2F
via IFTTT

Read More

Grip strength, gait may soon measure biological lifespan, says Dr Prateek Sharma

Genes influence lifespan, but lifestyle and environment are crucial for longevity. Biological age will soon be measured by new indicators beyond chronological age. Healthy life expectancy boosts India's economy significantly, benefiting all stakeholders. The focus is shifting from lifespan to healthspan, adding energy and reducing disease. Evidence-based nutrition science is vital, dispelling myths about magic diets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wZ3IEiA
via IFTTT

Read More

Kedaara Capital bets on India’s orthopaedic market with $200 million Tynor deal

Kedaara Capital has acquired a majority stake in Tynor Orthotics for $200 million. This private equity firm is expanding its medical devices portfolio with this significant investment. Tynor Orthotics is a leading Indian manufacturer of orthopaedic and rehabilitation products. The company has a wide distribution network reaching many countries globally. Kedaara will partner with existing promoters and management to drive future growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sWElm3B
via IFTTT

Read More

Biocon arm gets Japan nod for cancer drug pegfilgrastim biosimilar

In a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer supportive care drug is designed to mitigate infection risks following chemotherapy. Developed as a rival to Neulasta, Sandoz KK will handle its exclusive promotion and distribution. This approval marks a pivotal step in expanding Biocon's biosimilar range and improving patient accessibility worldwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aHGz7cR
via IFTTT

Read More

Govt eases loan licence requirement for 'outsourced' sterilisation of medical gear

Medical device makers now avoid loan licenses for outsourced sterilization services. This change simplifies business while industry leaders express concerns about new labeling rules. Printing sterilizer license numbers on device labels may hinder export flexibility and cause shipment delays. Manufacturers worry about losing the ability to choose the fastest available sterilization facility. The government also recognized the European Union for clinical investigation waivers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gTqpi32
via IFTTT

Read More

DRL, Emcure get approval to make breakthrough HIV drug

India's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for local clinical trials. This move will improve access to the HIV prevention injection. Lenacapavir is a breakthrough twice-yearly injection for HIV prevention. Patient groups had urged the regulator to expedite this process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uDHPmRf
via IFTTT

Read More

Adani Group to set up 2,000-bed hospital in Bengal, 1,000 beds to be free

The Adani Group plans to establish a significant 2,000-bed hospital in New Town. Half of these beds will be allocated for free treatment of the poor. West Bengal Chief Minister Suvendu Adhikari confirmed this development. He stated that Karan Adani had met him regarding the project. Gautam Adani has sent a commitment letter to begin work soon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fwDN7Sk
via IFTTT

Read More

USFDA ends inspection of Aurobindo Pharma arm's facility with 4 observations

Aurobindo Pharma announced its subsidiary Lannett Company LLC's facility inspection concluded. The US Food and Drug Administration conducted this routine inspection from August 17-21, 2026. Four procedural observations were noted during the Seymour, USA facility's review. The company will provide its response to the USFDA within the required timeframe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vwhXlj3
via IFTTT

Read More

Indian pharma has little reason to fear Trump

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5tyzLi0
via IFTTT

Read More

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark

A Delhi court has permanently stopped Sainus Pharmaceutical Private Limited from using the 'Udaan' trademark. This ruling came after RSPL Health Private Limited filed a case alleging trademark infringement. RSPL Health, known for its 'Ghari' detergent brand, had registered its 'Udan' mark earlier. The court found Sainus Pharma's mark to be identical and deceptively similar to RSPL's registered trademark.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hBDI0m6
via IFTTT

Read More

Govt tightens rules on combinations containing 2 chemical compounds for young children

The government has restricted fixed-dose combinations containing Chlorpheniramine Maleate and Phenylephrine Hydrochloride. These medicines are now prohibited for use in children below four years of age. Manufacturers must clearly display a warning on all associated product packaging. This action follows recommendations from an expert committee and the Drugs Technical Advisory Board. The notification is effective from its publication date in the official gazette.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g6Cole3
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT

Read More

Medical devices industry needs to focus more on local value addition: Pharma Secy

The medical devices sector must increase local value addition and component manufacturing. Government officials are open to industry suggestions for PLI scheme beneficiaries. Many companies invested but could not claim incentives for various reasons. The government aims to incentivize component makers more than assembly operations. Increased domestic value addition is a key objective for the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5IK8kP
via IFTTT

Read More

Delhi High Court rules in favour of Dr Reddy's Labs in trademark row with Razenta

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bBO9zsi
via IFTTT

Read More

Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT

Read More

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are underway for lung, bladder, kidney, pancreatic, and stomach cancers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p51oUgc
via IFTTT

Read More

Pharma giant Cipla completes merger with wholly-owned subsidiary Inzpera Health Sciences

Pharmaceuticals giant Cipla announced its merger with Inzpera Healthsciences Limited on Wednesday. This consolidation aims for more efficient resource utilisation and greater economies of scale. The merger will improve operating parameters and maximise shareholder value through integration. Greater efficiency in cash management and access to cash flows is also expected. Business processes will be simplified, reducing administrative expenses and compliance costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CBf5Zeo
via IFTTT

Read More

Lord’s Mark Industries announces license for biomescan analytics platform

Lord's Mark Industries has obtained a license for its groundbreaking Biomescan Analytics Platform, which specializes in assessing the gut microbiome to deliver customized health insights. With ambitious plans to set up 3,000 health centers across India in the next three years, the initiative aims to offer gut assessments and personalized nutritional advice, promoting proactive health and enhancing long-term wellness outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xolc8ZJ
via IFTTT

Read More

Apollo Hospitals extends services to all seven days of week

Apollo Hospitals will now offer routine healthcare services on Sundays. This initiative extends outpatient consultations and diagnostic services to weekends. Scheduled procedures and follow-up care will also be available, complementing existing emergency services. The hospital group aims to improve access for busy professionals and families. This move reinforces Apollo's commitment to preventive and timely medical care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYSO56a
via IFTTT

Read More

Manipal Health Enterprises to acquire Kinder Women's Hospital in Bengaluru

Manipal Health Enterprises will acquire Kinder Women's Hospital in Bengaluru for Rs 130 crore. This business transfer agreement involves acquiring the hospital's entire operations and assets. The acquisition strengthens Manipal Hospitals' position in a growing Bengaluru healthcare market. It will also expand access to their clinical expertise and capabilities for more patients. This move complements their existing healthcare ecosystem in the Whitefield micro-market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YGcSIrw
via IFTTT

Read More